Critical Comparison: Miragen Therapeutics (MGEN) and BG Medicine (BGMD)

Miragen Therapeutics (NASDAQ: MGEN) and BG Medicine (OTCMKTS:BGMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Miragen Therapeutics and BG Medicine, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Miragen Therapeutics 0 0 3 0 3.00
BG Medicine 0 0 0 0 N/A

Miragen Therapeutics currently has a consensus price target of $24.00, indicating a potential upside of 200.00%. Given Miragen Therapeutics’ higher probable upside, equities research analysts plainly believe Miragen Therapeutics is more favorable than BG Medicine.

Insider and Institutional Ownership

22.6% of Miragen Therapeutics shares are held by institutional investors. 44.4% of Miragen Therapeutics shares are held by insiders. Comparatively, 6.5% of BG Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Miragen Therapeutics and BG Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Miragen Therapeutics -720.38% -80.31% -64.59%
BG Medicine -311.03% N/A -131.82%

Valuation & Earnings

This table compares Miragen Therapeutics and BG Medicine’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Miragen Therapeutics $3.34 million 53.44 -$12.67 million ($8.93) -0.90
BG Medicine $1.57 million 0.25 -$5.30 million N/A N/A

BG Medicine has lower revenue, but higher earnings than Miragen Therapeutics.

Volatility and Risk

Miragen Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, BG Medicine has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Summary

Miragen Therapeutics beats BG Medicine on 8 of the 11 factors compared between the two stocks.

Miragen Therapeutics Company Profile

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

BG Medicine Company Profile

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Receive News & Ratings for Miragen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply